Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>

20081,001 citationsJournal Articlebronze Open Access

Authors

Charles D. Blanke · Oregon Health & Science University

George D. Demetri · Fox Chase Cancer Center

Margaret von Mehren · Dana-Farber Cancer Institute

Michael C. Heinrich · Fox Chase Cancer Center

Burton Eisenberg · Dana-Farber Cancer Institute

Jonathan A. Fletcher · Novartis (Switzerland)

Christopher L. Corless

Abstract

Nearly 50% of patients with advanced GIST who were treated with imatinib mesylate survived for more than 5 years, regardless of a 400 or 600 mg/d starting dose.

Topics & Keywords

Gastrointestinal Tumor Research and Treatment Platelet Disorders and Treatments Gastrointestinal disorders and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 26, Issue 4, pp. 620-625

DOI: 10.1200/jco.2007.13.4403

Field-Weighted Citation Impact: 47.66